Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study

Table 3 Summary of AEs

	AEs of interest		Other AEs		SAEs^a
	Patients, n (%) (N = 125)	AEs, n	Patients, n (%) (N = 125)	AEs, n	Patients n (%) (N = 125)	AEs, n
Any AE	15 (12.0)	20	20 (16.0)	29	5 (4.0)	5
Severity of AE^b
Mild	10 (8.0)	13	11 (8.8)	14	0	0
Moderate	5 (4.0)	6	6 (4.8)	12	1 (0.8)	1
Severe	1 (0.8)	1	3 (2.4)	3	4 (3.2)	4
AEs considered related to Ig20Gly
Related	7 (5.6)	8	3 (2.4)	4	0	0
Possibly related	5 (4.0)	5	4 (3.2)	6	1 (0.8)	1
Probably related	2 (1.6)	2	2 (1.6)	2	0	0

^a SAEs were defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, or is an important medical event
^b AE severity was defined as follows: mild – usually transient and may require only minimal treatment or therapeutic intervention (the event does not generally interfere with usual activities of daily living); moderate – usually alleviated with specific therapeutic intervention (the event interferes with usual activities of daily living, causing discomfort, but poses no significant or permanent risk of harm to the patient); severe – interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention

ISSN: 1710-1492